Abstract Tissue hypoxia results from an inadequate supply of oxygen (O 2 ) that compromises biological functions. Structural and functional abnormalities of the tumour vasculature together with altered diffusion conditions inside the tumour seem to be the main causes of tumour hypoxia. Evidence from experimental and clinical studies points to a role for tumour hypoxia in tumour propagation, resistance to therapy and malignant progression. This has led to the development of assays for the detection of hypoxia in patients in order to predict outcome and identify patients with a worse prognosis and/or patients that would benefit from appropriate treatments. A variety of invasive and noninvasive approaches have been developed to measure tumour oxygenation including oxygen-sensitive electrodes and hypoxia marker techniques using various labels that can be detected by different methods such as positron emission tomography (PET), single photon emission computed tomography (SPECT), magnetic resonance imaging (MRI), autoradiography and immunohistochemistry. This review aims to give a detailed overview of non-invasive molecular imaging modalities with radiolabelled PET and SPECT tracers that are available to measure tumour hypoxia.
cell carcinoma of the cervix [4, 5] , head and neck [6] [7] [8] , and soft-tissue sarcomas [9] .
Many of the adaptations to tumour hypoxia seem to be orchestrated by the transcription factor hypoxia-inducible factor (HIF)-1, which has been verified as a master regulator of oxygen homeostasis under hypoxic conditions. Its oxygen-dependent activity is regulated in a delicate interplay between several factors in which a family of prolyl hydroxylase domain-containing proteins or PHDs 1-3, the von Hippel-Lindau (VHL) tumour suppressor protein (pVHL) and an E3 ubiquitin ligase complex, amongst many others, play an important role. The HIF-1 pathway mediates critical hypoxic adaptations by the induction of target genes involved in glucose metabolism, angiogenesis, erythropoiesis and apoptosis. These target genes include vascular endothelial growth factor (VEGF), facilitative glucose transporters (GLUTs), hexokinases (HKs), erythropoietin (EPO), carbonic anhydrase IX (CAIX), … The resulting adaptive changes in the proteome and genome of the tumour cells are believed to lead to more aggressive clones which are better adapted to survive in their compromised situation. Subsequent selection and clonal expansion of these clones lead to a more adapted and aggressive tumour cell population [1] [2] [3] . As noted above, the presence of tumour hypoxia appears to impair the effectiveness of common anticancer therapies like radiotherapy (RT) and chemotherapy. Hypoxia-induced radioresistance is multifactorial. Besides the above-mentioned proteomic and genomic changes that most likely contribute to resistance by increasing the number of mutated cells that are more resistant to apoptosis and by causing upregulation of several stress proteins, the main reason for radioresistance is the intrinsic dependence of RT on oxygen to cause damage to the tumour cell. For damage to be inflicted on tumour cells by ionizing radiation, the presence of oxygen is necessary because it mediates DNA damage through formation of free radicals by interaction of ionizing radiation with intracellular water. Hypoxia has also been shown to reduce chemotherapeutic efficacy by causing cells within hypoxic regions to cycle more slowly and by providing a selection mechanism for cells with reduced susceptibility for apoptosis. Additionally, due to limited drug penetration within solid tumours, hypoxic regions are often protected from the cytotoxic effects of chemotherapeutic agents further reducing drug efficacy [1] [2] [3] .
All these mechanisms together ensure that tumour hypoxia is a negative prognostic factor. In order to predict outcome and identify patients with a worse prognosis and/ or patients that would benefit from appropriate treatments, in vivo measurement of tumour hypoxia is required. At present, the gold standard for direct in vivo determination of tumour oxygenation is a commercially available oxygen electrode, commonly referred to as the Eppendorf electrode.
As mentioned above, tumour oxygenation measurements obtained with this technique correlated well with clinical outcome in several clinical trials [4] [5] [6] [7] [8] [9] . However, this technically demanding procedure has a number of drawbacks and limitations like its sensitivity for sampling errors, its invasive nature and the fact that only easily accessible tumours can be studied. Therefore, the search for a noninvasive assay for tumour hypoxia continues. Non-invasive measurement of tumour hypoxia with PET and SPECT will be discussed below.
Non-invasive measurement of tumour hypoxia with PET
Nitroimidazole compounds
These compounds are reduced into reactive intermediary metabolites by intracellular reductases in a process which is directly related to the level of oxygenation/hypoxia. This causes a gradient which is favourable for detection of hypoxic cells. Subsequently, these metabolites covalently bind to thiol groups of intracellular proteins and thereby accumulate within viable hypoxic cells. When labelled with a PET tracer, these chemicals can be detected using PET imaging methods. Several nitroimidazole compounds with different properties and labelled with different PET radionuclides have been described [10, 11] . [44] .
Newer agents based on the azomycin-nucleoside structure such as iodoazomycin galactoside (IAZG) [69, 70] and iodoazomycin galactopyranoside (IAZGP) [71] 64 Cu-labelled bis (thiosemicarbazone) complexes were prepared and tested for tumour hypoxia selectivity by incubation with CHO320 Chinese hamster ovary cells under normoxic and hypoxic conditions. A number of molecules, including 64 Cu-ATSM, showed significant hypoxia selectivity [88] . Later, attempts were made to improve the hypoxia selectivity of the copper complexes by identification of the physicochemical properties that control hypoxia selectivity [89] . Lewis Cu-ATSM in vivo in a murine animal model. 64 Cu-ATSM was selectively trapped in vitro in EMT6 cells under hypoxic conditions and in vivo in solid EMT6 tumours, confirming its role as an agent to successfully detect tumour hypoxia [90] . A study by Burgman et al. indicated, after determining the in vitro uptake of 64 Cu-ATSM as a function of oxygenation conditions and incubation time in several tumour cell lines of rodent and human origin, that the uptake and retention of 64 Cu-ATSM and their relation to oxygenation conditions were cell line dependent [91] . The pO 2 dependence of Cu-ATSM was confirmed in a 9L gliosarcoma rat model by comparison of Cu-ATSM uptake with direct oxygen measurements using needle oxygen electrodes while tumour oxygen concentration was manipulated [92] . A study by Yuan et al., on the other hand, concluded after comparing the autoradiographic distributions of 64 Cu-ATSM with the hypoxia markers EF5, pimonidazole and CAIX in R3230 mammary adenocarcinomas, fibrosarcomas and 9L gliomas that 64 Cu-ATSM is a suitable PET hypoxia marker in most tumour types, but not for all [93] .
A number of studies compared 64 imaging, indicating a tumour-specific dependence of 64 Cu-ATSM uptake and retention under hypoxic conditions [94] . In another study, 64 Cu-ATSM tumour uptake was unable to predictably detect changes in varying amounts of tumour hypoxia when oxygenation levels in SCCVII tumours were modulated, whereas [ 18 F]FMISO tumour uptake was more responsive to changing levels of hypoxia. Tumour hypoxia was also assessed independently using pimonidazole [95] .
Two studies comparing 64 Cu-ATSM uptake with [ 18 F] FDG uptake in different animal models concluded that both tracers have a different distribution pattern [81, 82] . 64 Cu-ATSM accumulated in hypoxic but viable tumour cells, whereas [ 18 F]FDG uptake was highest in pre-necrotic regions where the cells were believed to lack the necessary reductive mechanisms to accumulate 64 Cu-ATSM [81] . It was also shown that regions with high 64 Cu-ATSM uptake were hypovascular and consisted of tumour cells arrested in the cell cycle, whereas regions with high [
18 F]FDG uptake were hypervascular and consisted of proliferating cells, as confirmed by histological analysis with Ki67, CD34 and TUNEL assay [82] 64 Cu-ATSM at 10 min or 24 h. A poor correlation existed however between 64 Cu-ATSM (10 min) and [ 18 F]FDG [22] . Clinical data: In numerous studies, 60 Cu-ATSM uptake proved to be predictive of tumour behaviour and response to therapy in patients with non-small cell lung cancer [83] , cervical cancer [96, 97] and rectal carcinoma [84] . In a study by Dehdashti et al. in 14 patients with biopsy-proven cervical cancer, an arbitrarily selected tumour to muscle threshold of 3.5 was able to discriminate those patients that were likely to develop recurrence so that 60 Cu-ATSM uptake was inversely related to progression-free survival and overall survival. Additionally, no correlation was found between 60 Cu-ATSM uptake and [ 18 F]FDG uptake [96] . To confirm these results, a study with a larger group of patients was performed by the same group. Tumour 60 Cu-ATSM uptake (T/M threshold of 3.5) in 38 patients with cervical cancer was inversely related to progression-free survival and cause-specific survival. Again, no correlation was found between 60 Cu-ATSM uptake and [
18 F]FDG uptake [97] . Similar results were obtained in a study where semiquantitative analysis of the 60 Cu-ATSM tumour to muscle ratio in 14 patients with non-small cell lung cancer was able to discriminate responders from non-responders. However, there was no significant difference in mean tumour SUV of non-responders and responders. Again, no correlation was found between 60 Cu-ATSM uptake and [ 18 F]FDG uptake [83] . In a recent study, an effort was made to predict the response of rectal cancers to neoadjuvant chemoradiotherapy and prognosis in 17 patients. The results of this small pilot study suggested that 60 Cu-ATSM tumour to muscle ratio may be predictive of survival and, possibly, tumour response. Again, no correlation was found between 60 Cu-ATSM uptake and [ 18 F]FDG uptake [84] . To determine if hypoxia-related molecular markers were associated with 60 Cu-ATSM retention, the PET imaging data of 15 patients with cancer of the cervix were compared with the expression of tissue molecular markers, which included VEGF, cyclo-oxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), carbonic anhydrase IX (CA-9) and apoptotic index. Hypoxia as identified with 60 Cu-ATSM imaging was correlated with overexpression of VEGF, EGFR, COX-2, CA-9, an increase in apoptosis and a poor outcome [98] . Chao et al. further demonstrated the feasibility of using 60 Cu-ATSM imaging to identify the hypoxic tumour subvolume through coregistration of CT and 60 Cu-ATSM PET images in order to plan a patient's course of radiotherapy and perform intensity-modulated radiation therapy (IMRT) [99] . As most clinical Cu-ATSM studies used the agent with the short-lived positron-emitting radionuclide of copper, 60 Cu, a recent study compared the image quality and tumour uptake of 60 Cu-ATSM and 64 Cu-ATSM in ten patients with cervical carcinoma to evaluate the use of Cu-ATSM with one of the longer-lived positron-emitting copper nuclides, 64 Cu. It was concluded that 64 Cu-ATSM was a safe radiopharmaceutical that can be used to obtain high quality images of tumour hypoxia in human cancers [100] .
Non-invasive measurement of tumour hypoxia with SPECT Tc]HMPAO, and severe perfusion deficits were usually associated with an increased uptake of the hypoxic marker [104] . After observing uptake of radioactivity in the brain after administration of [ 123 I]IAZA, a study was undertaken to investigate the proposed metabolites of IAZA in normal and tumour-bearing murine models. Neither of the proposed metabolites' biodistribution did support its involvement in brain radioactivity uptake in patients [105] . A study investigating the use of [ ]IAZA, total radioactivity kinetics and the radiation dosimetry estimates for six healthy volunteers and concluded that all supported its clinical use for imaging tissue hypoxia [107, 108] .
Newer agents based on the azomycin-nucleoside structure such as IAZG [109, 110] , iodoazomycin pyranoside (IAZP) [111] , IAZGP [112, 113] and iodoazomycin xylopyranoside (IAZXP) [109] Tc-labelled 2-nitroimidazole to be widely studied for imaging [114] . A number of experimental studies have evaluated the use of BMS 181321 for the detection of ischaemic and hypoxic myocardium [115] [116] [117] [118] . Ballinger et al. showed selective accumulation in hypoxic cells in vitro and in vivo but concluded that BMS 181321 was not optimal for tumour hypoxia imaging because of in vitro and in vivo instabilities and a high partition coefficient, resulting in slow clearance from the blood and high background levels in normal tissues [119] .
Pre-clinical data: BRU59-21, previously known as BMS 194796, is a second-generation analogue of BMS 181321 which shows greater stability in vitro and more rapid clearance from the circulation in vivo, resulting in higher tumour to blood and tumour to muscle ratios. It showed selective localization in tumour cells incubated under hypoxic conditions and following intravenous injection in animal models representative of poorly perfused tumours [120] . In a study by Zhang et al., BRU59-21 and HL91 were compared directly in the same in vitro systems. Both tracers proved suitable for hypoxia imaging [121] .
Clinical 99m Tc]HL91 is a safe radioligand and that metabolic binding in a large fraction but not all of local SCCHN recurrences may be expected [134] . Finally, in a study with 32 patients with non-small cell lung cancer, Li et al. showed that hypoxia imaging with [ 99m Tc]HL91 before radiotherapy may predict tumour response and patient survival [135] .
Discussion
There are several prerequisites to which the ideal noninvasive hypoxic marker should comply: (1) It should be specific for hypoxia and thus distinguish normoxia, hypoxia and anoxia or necrosis. (2) It should image acute and chronic hypoxia and possibly distinguish between both. (3) It should be simple, non-toxic, fast, easy to perform and allow repeated measurements. (4) It should be lipophilic to have a homogeneous biodistribution in all tissues including tumours but at the same time hydrophilic to have a faster elimination, thus allowing larger tumour to normal tissue ratio of radioactivity. (5) It should have little hypoxiaindependent degradation in vivo leading to non-specific tracer metabolites and/or little aspecific tissue binding, so that only oxygen-specific retention mechanisms determine the amount of tracer that is temporarily or permanently trapped. (6) It should reflect intracellular pO 2 rather than blood flow or some consequence of subsequent biochemistry. (7) It should be sensitive at pO 2 levels relevant to tumour therapy. (8) It should offer the ability to quantify. Unfortunately, none of the present hypoxia tracers available completely fulfils these requirements.
Although SPECT is more commonly used than PET, and, in particular, 99m Tc has a number of practical advantages that include ready availability at low cost, convenient half-life for hypoxia measurements and versatile chemistry as compared with 18 18 F]FMISO PET imaging has been used as a prognostic indicator in several other studies. It has, however, failed to gain wider acceptance for routine clinical application because of a number of limitations such as: (1) slow accumulation in hypoxic tumours; (2) a low target to background ratio due to high non-specific binding resulting from its relatively high lipophilicity; and (3) significant non-oxygen dependent metabolism leading to a considerable amount of radioactive metabolite products.
Several The molecule that holds the greatest promise for the future is Cu-ATSM. Although its mechanism of hypoxic retention is not yet fully elucidated, numerous in vitro and in vivo studies have shown its selectivity for hypoxic tissue. It has a small molecular weight and a high cell membrane permeability allowing it to diffuse easily from the bloodstream to surrounding cells. This combined with a rapid blood clearance and its rapid reduction and retention in hypoxic tissues ensures that Cu-ATSM shows a rapid delineation of tumour hypoxia and high tumour to background ratios. Clinical results clearly suggest further clinical evaluation is warranted and positive results are expected to follow.
Conclusion
As the importance of tumour hypoxia is being recognized, so is the importance of its detection. Because of the limitations of the current gold standard, a non-invasive technique to predict outcome and identify patients with a worse prognosis and/or patients that would benefit from appropriate treatments is needed. Several candidates are rapidly being developed and investigated. Of the several candidate techniques and molecules, each has its advantages and disadvantages, and it may be possible that a particular technique or molecule is best suited for a certain tumour type, grade or stage. Evaluation of the several candidate molecules is taking place in patients at this moment and it is hoped that this eventually will lead to further characterization and optimization.
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